Rallybio vs Exicure
RLYB and XCUR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RLYB and XCUR compare
Rallybio is the larger company, worth 12 times as much as Exicure ($82.3M against $7.1M).
Rallybio scores higher on the StockData Score (10 against 4 for Exicure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RLYB | XCUR |
|---|---|---|
| Size and price | ||
| Market cap | $82.3M | $7.1M |
| Share price | $15.29 | $1.08 |
| Change, 1 year | 199% | −70.9% |
| Change, 5 years | −85.5% | −98.5% |
| Beta (5Y) | 0.01 | −0.98 |
| Employees | 14 | 8 |
| StockData Score | ||
| Total score | 10 (better) | 4 |
| Valuation score | 2 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 3.4× | – |
| P/S | 190× | – |
| P/B | 0.9× (better) | 7.2× |
| Growth | ||
| Revenue growth (TTM) | −35.6% | – |
| Profitability | ||
| Operating margin | −5581% | – |
| Net margin | 6177% | – |
| Return on equity | 34.5% (better) | −168% |
| Return on invested capital | −718% (better) | −4377% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 28.87 (better) | 0.56 |
| Altman Z-score | 11.42 (better) | −27.36 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | – | 2.1% |
| Held by insiders | 72.6% | 92.6% |
| Insider net buying, 12 months | $4.2M (better) | −$11.6M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 2.6% | 10.8% |
Go deeper
- RLYB stock overview
- RLYB income statement
- RLYB valuation and score
- XCUR stock overview
- XCUR income statement
- XCUR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.